NCT06106646 Vitamin C to Decrease Effects of Smoking in Pregnancy on Infant Lung Function (VCSIP) Longer Term Follow Up
| NCT ID | NCT06106646 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Oregon Health and Science University |
| Condition | Asthma |
| Study Type | OBSERVATIONAL |
| Enrollment | 225 participants |
| Start Date | 2023-10-11 |
| Primary Completion | 2027-08 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 225 participants in total. It began in 2023-10-11 with a primary completion date of 2027-08.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The overall aims of this protocol are to determine whether prenatal supplementation with vitamin C to pregnant smokers can improve pulmonary function at 10 years of age in their offspring. This is an additional continuation of the Vitamin C to Decrease Effects of Smoking in Pregnancy on Infant Lung Function (VCSIP) trial, to follow the offspring through 10 years of age. The hypothesis for this protocol is an extension of the VCSIP trial that supplemental vitamin C in pregnant smokers can significantly improve their children's airway function tests. The investigators aim to demonstrate sustained improvement in airway/pulmonary function and trajectory through 10 years of age.
Eligibility Criteria
Inclusion Criteria: * Women and their offspring randomized to vitamin C versus placebo during pregnancy as well as pregnant nonsmokers and their offspring enrolled as the reference group in the original VCSIP study Exclusion Criteria: * participants who specifically withdraw consent
Contact & Investigator
Cindy McEvoy, MD, MCR
PRINCIPAL INVESTIGATOR
Oregon Health and Science University
Frequently Asked Questions
Who can join the NCT06106646 clinical trial?
This trial is open to participants of all sexes, aged 6 Years or older, up to 16 Years, studying Asthma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06106646 currently recruiting?
Yes, NCT06106646 is actively recruiting participants. Contact the research team at mcevoyc@ohsu.edu for enrollment information.
Where is the NCT06106646 trial being conducted?
This trial is being conducted at Indianapolis, United States, Portland, United States.
Who is sponsoring the NCT06106646 clinical trial?
NCT06106646 is sponsored by Oregon Health and Science University. The principal investigator is Cindy McEvoy, MD, MCR at Oregon Health and Science University. The trial plans to enroll 225 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.